Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Optic Neuropathy, Ischemic | 3 | 2022 | 8 | 1.730 |
Why?
|
| Multiple Sclerosis | 3 | 2021 | 66 | 1.550 |
Why?
|
| Optic Disk | 2 | 2021 | 21 | 1.420 |
Why?
|
| Optic Nerve Diseases | 3 | 2022 | 25 | 1.270 |
Why?
|
| Meningeal Neoplasms | 3 | 2023 | 52 | 1.240 |
Why?
|
| Vision Disorders | 2 | 2019 | 57 | 1.010 |
Why?
|
| Giant Cell Arteritis | 2 | 2021 | 12 | 0.940 |
Why?
|
| Esotropia | 1 | 2023 | 3 | 0.890 |
Why?
|
| Strabismus | 1 | 2023 | 15 | 0.880 |
Why?
|
| Papilledema | 2 | 2021 | 27 | 0.860 |
Why?
|
| Amiodarone | 1 | 2022 | 22 | 0.840 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 64 | 0.820 |
Why?
|
| Retinal Diseases | 2 | 2021 | 50 | 0.810 |
Why?
|
| Optic Neuritis | 2 | 2013 | 21 | 0.770 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2021 | 9 | 0.750 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 63 | 0.720 |
Why?
|
| Cataract | 1 | 2021 | 45 | 0.700 |
Why?
|
| Optic Nerve | 4 | 2022 | 50 | 0.670 |
Why?
|
| Retina | 1 | 2019 | 65 | 0.650 |
Why?
|
| Optic Atrophy | 1 | 2018 | 17 | 0.640 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2018 | 17 | 0.610 |
Why?
|
| Pseudotumor Cerebri | 1 | 2018 | 24 | 0.600 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2018 | 65 | 0.580 |
Why?
|
| Tomography, Optical Coherence | 4 | 2021 | 102 | 0.540 |
Why?
|
| Visual Acuity | 5 | 2018 | 138 | 0.450 |
Why?
|
| Malaria, Falciparum | 1 | 2013 | 13 | 0.450 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2019 | 1541 | 0.450 |
Why?
|
| Humans | 23 | 2023 | 50208 | 0.440 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2013 | 16 | 0.430 |
Why?
|
| Myasthenia Gravis | 1 | 2013 | 17 | 0.430 |
Why?
|
| Meningioma | 2 | 2010 | 46 | 0.420 |
Why?
|
| Stroke | 1 | 2018 | 493 | 0.420 |
Why?
|
| Eye Pain | 1 | 2010 | 4 | 0.370 |
Why?
|
| Sella Turcica | 1 | 2010 | 7 | 0.360 |
Why?
|
| Diplopia | 2 | 2023 | 20 | 0.360 |
Why?
|
| Visual Pathways | 1 | 2010 | 12 | 0.360 |
Why?
|
| Vision, Low | 1 | 2010 | 9 | 0.360 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 64 | 0.350 |
Why?
|
| Optic Disk Drusen | 1 | 2009 | 3 | 0.330 |
Why?
|
| Hemianopsia | 1 | 2009 | 5 | 0.330 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2008 | 8 | 0.320 |
Why?
|
| Female | 12 | 2023 | 26635 | 0.320 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 397 | 0.320 |
Why?
|
| Glioma | 1 | 2008 | 79 | 0.300 |
Why?
|
| Optic Nerve Injuries | 2 | 2022 | 7 | 0.300 |
Why?
|
| Radiation Injuries | 1 | 2008 | 112 | 0.290 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 605 | 0.280 |
Why?
|
| Adult | 6 | 2021 | 13324 | 0.260 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 1043 | 0.240 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 2954 | 0.230 |
Why?
|
| Demography | 1 | 2023 | 92 | 0.210 |
Why?
|
| Aged | 4 | 2023 | 9405 | 0.210 |
Why?
|
| Traction | 1 | 2021 | 7 | 0.200 |
Why?
|
| Cavernous Sinus | 1 | 2022 | 15 | 0.200 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2022 | 138 | 0.200 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2022 | 11 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 157 | 0.200 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 140 | 0.200 |
Why?
|
| Middle Aged | 6 | 2018 | 12206 | 0.190 |
Why?
|
| Macular Degeneration | 1 | 2021 | 47 | 0.190 |
Why?
|
| Embolization, Therapeutic | 1 | 2022 | 86 | 0.180 |
Why?
|
| Prednisone | 1 | 2021 | 101 | 0.180 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6134 | 0.170 |
Why?
|
| Methylprednisolone | 2 | 2018 | 38 | 0.170 |
Why?
|
| Decompression, Surgical | 2 | 2010 | 51 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 222 | 0.170 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 174 | 0.160 |
Why?
|
| Male | 6 | 2019 | 25399 | 0.160 |
Why?
|
| Spinal Puncture | 1 | 2018 | 16 | 0.150 |
Why?
|
| Phlebography | 1 | 2018 | 60 | 0.150 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2017 | 5 | 0.150 |
Why?
|
| Clomiphene | 1 | 2017 | 3 | 0.150 |
Why?
|
| Abducens Nerve Diseases | 1 | 2017 | 8 | 0.150 |
Why?
|
| Intracranial Pressure | 1 | 2017 | 30 | 0.140 |
Why?
|
| Intracranial Hypertension | 1 | 2017 | 31 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2018 | 226 | 0.130 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2015 | 6 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 831 | 0.120 |
Why?
|
| Exanthema | 1 | 2015 | 32 | 0.120 |
Why?
|
| Antimalarials | 1 | 2013 | 23 | 0.110 |
Why?
|
| Biopsy | 2 | 2021 | 590 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2013 | 5155 | 0.110 |
Why?
|
| Visual Fields | 2 | 2009 | 37 | 0.100 |
Why?
|
| Radiography | 1 | 2013 | 491 | 0.100 |
Why?
|
| Optic Chiasm | 1 | 2010 | 9 | 0.090 |
Why?
|
| Ocular Motility Disorders | 1 | 2010 | 17 | 0.090 |
Why?
|
| Progesterone | 1 | 2010 | 57 | 0.090 |
Why?
|
| Acute Disease | 2 | 2021 | 368 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1186 | 0.090 |
Why?
|
| Craniotomy | 1 | 2010 | 25 | 0.090 |
Why?
|
| Paranasal Sinuses | 1 | 2009 | 18 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2010 | 121 | 0.080 |
Why?
|
| False Negative Reactions | 1 | 2008 | 30 | 0.080 |
Why?
|
| Chordoma | 1 | 2008 | 8 | 0.080 |
Why?
|
| Skull Base Neoplasms | 1 | 2008 | 21 | 0.080 |
Why?
|
| Endoscopy | 1 | 2009 | 124 | 0.080 |
Why?
|
| Protons | 1 | 2008 | 69 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 1161 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 382 | 0.070 |
Why?
|
| Pregnancy | 1 | 2010 | 2604 | 0.050 |
Why?
|
| Lipids | 1 | 2022 | 148 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 225 | 0.050 |
Why?
|
| Scotoma | 1 | 2021 | 7 | 0.050 |
Why?
|
| Headache | 1 | 2022 | 76 | 0.050 |
Why?
|
| Fundus Oculi | 1 | 2021 | 25 | 0.050 |
Why?
|
| Temporal Arteries | 1 | 2021 | 15 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 231 | 0.050 |
Why?
|
| Fluorescein Angiography | 1 | 2021 | 32 | 0.050 |
Why?
|
| Mitochondria | 1 | 2022 | 404 | 0.040 |
Why?
|
| Minocycline | 1 | 2017 | 15 | 0.040 |
Why?
|
| Mice | 1 | 2022 | 5759 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 747 | 0.020 |
Why?
|
| Blindness | 1 | 2009 | 31 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3629 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2009 | 187 | 0.020 |
Why?
|
| Animals | 1 | 2022 | 13246 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 6390 | 0.020 |
Why?
|
| Young Adult | 1 | 2009 | 3981 | 0.010 |
Why?
|